Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma

Colorectal cancer

MSI-H immunotherapy, BRAF V600E, HER2 and KRAS G12C combinations.

SITC 2026 ESMO 202611 ASCO 2026 AACR 2026 ASH 2026

ESMO Congress 2026

23–27 Oct 2026, Madrid · Annals of Oncology, vol. 37 supplement

The ESMO 2026 abstract supplement was not in Crossref on 11 Nov 2026 and ESMO's congress platform blocks automated access, so ESMO abstracts here come from web research: each row was found on a published congress report and verified against it.

Headline and verified abstracts

11 abstracts found by Parallel web research on 2026-11-11 and verified: 11 against the saved source excerpt. Rows that could not be verified were dropped. Titles and metadata only; abstract text is not stored.

LBA29
Late-breaking
IROCAS: A randomized phase III trial of adjuvant treatment intensification with mFOLFIRINOX versus mFOLFOX6 in high-risk stage III (T4 and/or N2) colon cancer
Jaafar BennounaIROCASNCT02967289mFOLFIRINOXmFOLFOX6
Matches source excerptcslide.ctimeetingtech.com
LBA30
Late-breaking
Omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) versus placebo after resection of colorectal cancer liver metastases (EMT2): A multicentre, double-blind, randomised phase 3 trial
Mark A. HullEMT2NCT03428477eicosapentaenoic acid (EPA)placebo
Matches source excerptcslide.ctimeetingtech.com
LBA31
Late-breaking
Biweekly versus conventional trifluridine/tipiracil plus bevacizumab for refractory metastatic colorectal cancer: The pragmatic phase 3 PRABITAS trial
Hiroya TaniguchiPRABITAStrifluridine/tipiracilbevacizumab
Matches source excerptcslide.ctimeetingtech.com
LBA32
Late-breaking
Final overall survival results from CheckMate 8HW: Nivolumab plus ipilimumab versus nivolumab or chemotherapy in MSI-H/dMMR metastatic colorectal cancer
Sara LonardiCheckMate 8HWNCT04008030nivolumabipilimumabchemotherapy
Matches source excerptcslide.ctimeetingtech.com
LBA87
Late-breaking
Clinical complete response with dostarlimab monotherapy in dMMR/MSI-H locally advanced rectal cancer (LARC): First results from the global registrational AZUR-1 trial
Andrea CercekAZUR-1NCT05723562dostarlimab
Matches source excerptcslide.ctimeetingtech.com
3530O
Oral presentation
Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (LARC): The phase 3 UNION trial
Tao Zhang (presented by Zhen Yu Lin)UNIONNCT04928807camrelizumabcapecitabineoxaliplatin
Matches source excerptcslide.ctimeetingtech.com
787RO
Rapid oral
Circulating tumor DNA (ctDNA)-guided re-treatment (re-tx) with encorafenib and cetuximab (EC) in patients (pts) with chemorefractory BRAFV600E mutated metastatic colorectal cancer (mCRC): The proof-of-concept single arm phase II BRICKET trial by GONO
Vittorio Studiale (presented by Marco Maria Germani)BRICKETencorafenibcetuximab
Matches source excerptcslide.ctimeetingtech.com
788RO
Rapid oral
Encorafenib plus cetuximab (EC) beyond progression in combination with FOLFIRI in BRAF V600E metastatic colorectal cancer (mCRC) patients (pts) progressing on EC: Results from the ECLYPse phase II trial
Maria Alessandra CalegariECLYPseNCT06640166encorafenibcetuximabFOLFIRI
Matches source excerptcslide.ctimeetingtech.com
789RO
Rapid oral
TRIDENTE: A phase II study of rechallenge with encorafenib (ENCO), binimetinib (BINI), and cetuximab (CET) in BRAF V600E-mutant metastatic colorectal cancer (mCRC)
Daisuke KotaniTRIDENTEencorafenibbinimetinibcetuximab
Matches source excerptcslide.ctimeetingtech.com
790RO
Rapid oral
Preliminary clinical results of QTX3034, an oral G12D-preferring KRAS inhibitor, in combination with cetuximab ± mFOLFOX6 in patients with KRASG12D-mutated colorectal cancer (CRC)
Ignacio Garrido-LagunaQTX3034-001NCT06227377QTX3034cetuximabmFOLFOX6
Matches source excerptcslide.ctimeetingtech.com
791RO
Rapid oral
Long-term follow-up of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab (Bev) vs standard of care (SOC) in patients (pts) with 3L+ colorectal cancer (CRC): Updated results of a phase 1 study
Michael CecchiniNCT05029882telisotuzumab adizutecan (ABBV-400, Temab-A)bevacizumabtrifluridine/tipiracil (TAS-102)
Matches source excerptcslide.ctimeetingtech.com

Indexed in Crossref

The ESMO Congress 2026 supplement (Annals of Oncology, vol. 37 supplement) was not in Crossref when last checked on 11 Nov 2026. The verified abstracts above come from web research instead.